Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Non-Current Assets (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Non-Current Assets for 9 consecutive years, with $11.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 7.28% to $11.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.7 million through Dec 2025, down 7.28% year-over-year, with the annual reading at $11.7 million for FY2025, 7.28% down from the prior year.
  • Non-Current Assets hit $11.7 million in Q4 2025 for Protagonist Therapeutics, down from $115.3 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $136.3 million in Q1 2025 to a low of $1.7 million in Q1 2024.
  • Historically, Non-Current Assets has averaged $35.0 million across 5 years, with a median of $9.3 million in 2021.
  • Biggest five-year swings in Non-Current Assets: crashed 87.78% in 2022 and later skyrocketed 7809.0% in 2025.
  • Year by year, Non-Current Assets stood at $7.0 million in 2021, then tumbled by 33.52% to $4.6 million in 2022, then tumbled by 53.55% to $2.1 million in 2023, then soared by 486.64% to $12.6 million in 2024, then fell by 7.28% to $11.7 million in 2025.
  • Business Quant data shows Non-Current Assets for PTGX at $11.7 million in Q4 2025, $115.3 million in Q3 2025, and $115.5 million in Q2 2025.